Overview

Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Study investigators will examine the absorption characteristics of apixaban, a direct-acting oral anticoagulation, in patients who have underwent a particular kind of surgery (pancreaticoduodenectomy) which involves resection of the duodenum.
Phase:
Phase 1
Details
Lead Sponsor:
Thomas Jefferson University
Treatments:
Apixaban